《新股消息》醫美股愛美客(300896.SZ)擬發行H股在港上市
醫美股愛美客(300896.SZ)公佈,董事會同意公司發行境外上市外資股(H股)並申請在香港聯交所主板掛牌上市,爲完成本次發行上市,董事會同意公司轉爲境外募集股份有限公司。
公司獨立董事發表獨立意見,認爲本次發行上市有利於滿足公司的業務發展需求,深入推進公司國際化戰略,並進一步提升公司的經營管理水平,增強公司競爭力,並同意將該議案提交公司股東大會審議。
公司成立於2004年,立足於生物醫用軟組織修復材料的研發和轉化,是國內生物醫用軟組織材料創新型企業,已成功實現透明質酸鈉填充劑系列產品及面部埋植線的產業化。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.